Signaturefd LLC Grows Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Signaturefd LLC raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 12.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,138 shares of the biotechnology company’s stock after acquiring an additional 666 shares during the period. Signaturefd LLC’s holdings in Exelixis were worth $159,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Farallon Capital Management LLC increased its holdings in shares of Exelixis by 1.6% in the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after purchasing an additional 424,000 shares during the period. Renaissance Technologies LLC increased its stake in Exelixis by 0.4% in the 2nd quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company’s stock valued at $340,714,000 after buying an additional 61,350 shares during the period. LSV Asset Management raised its position in Exelixis by 107.7% during the 2nd quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock worth $129,511,000 after buying an additional 2,989,021 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Exelixis by 7.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock worth $115,434,000 after buying an additional 349,837 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Exelixis by 12.7% in the 2nd quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock worth $73,425,000 after acquiring an additional 370,199 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EXEL has been the topic of a number of recent analyst reports. The Goldman Sachs Group upgraded shares of Exelixis to a “strong sell” rating in a research note on Tuesday, October 15th. Bank of America boosted their target price on Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Morgan Stanley raised their price target on Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, October 11th. TD Cowen lifted their price target on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Royal Bank of Canada increased their price objective on Exelixis from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.57.

Insiders Place Their Bets

In other news, EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the sale, the executive vice president now directly owns 605,325 shares in the company, valued at $15,968,473.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $26.38, for a total value of $659,500.00. Following the completion of the transaction, the executive vice president now owns 605,325 shares of the company’s stock, valued at $15,968,473.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Christopher J. Senner sold 125,000 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the transaction, the chief financial officer now directly owns 721,680 shares in the company, valued at $19,622,479.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 327,858 shares of company stock valued at $8,640,129. Corporate insiders own 2.85% of the company’s stock.

Exelixis Trading Down 0.9 %

NASDAQ:EXEL opened at $27.87 on Monday. The company has a market capitalization of $7.95 billion, a P/E ratio of 24.03, a price-to-earnings-growth ratio of 0.61 and a beta of 0.54. The firm has a 50-day moving average price of $26.61 and a two-hundred day moving average price of $24.01. Exelixis, Inc. has a twelve month low of $19.20 and a twelve month high of $29.75.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The business had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million. On average, equities research analysts predict that Exelixis, Inc. will post 1.58 earnings per share for the current year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.